XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues $ 35,694 $ 39,488 $ 120,604 $ 114,096
Cost of products sold 27,012 29,714 88,889 86,298
Gross profit 8,682 9,774 31,715 27,798
Operating expenses:        
Research and development 2,101 1,869 5,854 5,679
Selling, general and administrative 6,070 5,770 17,370 16,293
Total operating expenses 8,171 7,639 23,224 21,972
Operating income 511 2,135 8,491 5,826
Other (expense) income:        
Interest and financing expense (173) (586) (1,111) (1,450)
Miscellaneous income 15 200 426 1,628
Total other (expense) income (158) (386) (685) 178
Income before income taxes 353 1,749 7,806 6,004
Income tax provision 74 446 1,630 1,688
Net income 279 1,303 6,176 4,316
Net income (loss) attributable to non-controlling interest 21 (27) 58 (8)
Net income attributable to Ultralife Corporation 258 1,330 6,118 4,324
Other comprehensive loss:        
Foreign currency translation adjustments 811 (330) 576 (426)
Comprehensive income attributable to Ultralife Corporation $ 1,069 $ 1,000 $ 6,694 $ 3,898
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.02 $ 0.08 $ 0.37 $ 0.27
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.02 $ 0.08 $ 0.37 $ 0.27
Weighted average shares outstanding – basic (in shares) 16,625 16,238 16,530 16,172
Potential common shares (in shares) 249 65 212 2
Weighted average shares outstanding - diluted (in shares) 16,874 16,303 16,742 16,174